Experimental vaccine aims to boost immune attack on Hard-to-Treat cancers
NCT ID NCT04041310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new genetic vaccine called Nous-209, given together with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced MSI-H or dMMR solid tumors (colorectal, gastric, or gastro-esophageal junction cancers). The vaccine is designed to train the immune system to recognize and attack cancer cells. The trial has two phases: phase I checks safety and finds the best dose, while phase II looks at how well the combination shrinks tumors. About 115 participants are enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nous-209 genetic vaccine (GAd20-209-FSP and MVA-209-FSP) plus pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat MSI-H solid tumors, potentially improving tumor shrinkage and disease control.
What could go wrong
This is an early-phase trial (phase I/II) with a small number of participants, so results may not confirm efficacy or safety. The vaccine is experimental, and side effects or lack of response are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOUS Policlinico Le Scotte
Siena, 53100, Italy
-
Aorn Sg Moscati
Avellino, 83100, Italy
-
Boca Raton Clinical Research
Plantation, Florida, 33322, United States
-
CHU de Liège
Liège, 4000, Belgium
-
Candiolo cancer Center,FPO IRCCS
Candiolo, 10060, Italy
-
Centre Hospitalier de l'Ardenne - Libramont - Clinique du Sein
Libramont, 6800, Belgium
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
City of Hope Comprehensive Cancer Center
Irvine, California, 92618, United States
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Cliniques Universitaires Saint-Luc - Centre du Cancer
Brussels, 1200, Belgium
-
Complejo Asistencial de Salamanca
Salamanca, 37007, Spain
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Goshen Center for Cancer Care
Goshen, Indiana, 46526, United States
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, 15706, Spain
-
Hospital Del Mar
Barcelona, 08003, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, 28007, Spain
-
Hospital General Universitario de Valencia
Valencia, 46014, Spain
-
Hospital Universitari Dexeus
Barcelona, 08028, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
-
Hospital Universitario Virgen de las Nieves
Granada, 18014, Spain
-
Hospital Universitario de A Coruna
A Coruña, 15006, Spain
-
Hospital Vall d'Hebron
Barcelona, 08035, Spain
-
IRCCS Ospedale San Raffaele
Milan, 20132, Italy
-
Institut Catala d'Oncologia Hospitalet
Barcelona, 08908, Spain
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center (MDACC)
Houston, Texas, 77030, United States
-
Mount Sinai Hospital
Toronto, M5G 2M9, Canada
-
Mt. Sinai
Miami Beach, Florida, 33140, United States
-
NYU Langone Medical Center
New York, New York, 10016, United States
-
Ospedale Niguarda
Milan, 20162, Italy
-
Princess Margaret Cancer Center
Toronto, M5G 2M9, Canada
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90089, United States
-
USC Norris Comprehensive Cancer Center
Newport Beach, California, 92663, United States
-
University Clinical Hospital Valencia
Valencia, Spain
-
University College London Hospitals NHS Foundation Trust Cancer Clinical Trials Unit
London, United Kingdom
-
Washington University School of Medicine, Division of Oncology
St Louis, Missouri, 63110, United States
-
Weill Cornell Medicine / New York-Presbyterian Hospital
New York, New York, 10021, United States